公司资料
Coherus BioSciences, Inc. 股价、新闻与催化剂
- 股票代码:
- CHRS
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
1.15 USD (-4.17%)
收盘价
最后更新: 2026年8月17日
234M USD
市值
股价为何变动
The latest monitored company update is “Coherus Oncology Announces Special Dividend of Biosimilar Contingent Value Rights.” The corresponding closing-price reaction is not yet available.
公司概览
Immuno-Oncology Portfolio
Coherus Oncology develops antibody-based cancer therapies intended to overcome immune suppression in the tumor microenvironment. Its pipeline combines internally controlled candidates with toripalimab, marketed in the United States as LOQTORZI.
Casdozokitug
Casdozokitug is an anti-IL-27 antibody being studied with LOQTORZI in first-line hepatocellular carcinoma. The program targets IL-27-mediated immune suppression and is being evaluated in a randomized Phase 2 trial.
Tagmokitug
Tagmokitug is a CCR8-directed antibody designed to selectively deplete regulatory T cells in tumors. Combination studies with toripalimab span head and neck, upper gastrointestinal, esophageal and colorectal cancers.
未来催化剂
- Initial data from the first-line HCC Phase 2 study of casdozokitug around mid-2026.
- Initial Phase 1b tagmokitug combination data in second-line head and neck and upper gastrointestinal cancers in mid-2026.
- First tagmokitug combination data in esophageal squamous-cell carcinoma in the second half of 2026.
- Initial tagmokitug combination data in late-line colorectal cancer in the second half of 2026.
近期新闻
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。